362 related articles for article (PubMed ID: 25456764)
1. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
[No Abstract] [Full Text] [Related]
2. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PCSK9: is this the way forward for managing residual risk?
Chowdhury SR; Rees A
Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
[No Abstract] [Full Text] [Related]
4. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
5. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 inhibitors.
Farnier M
Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
White CM
Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
[TBL] [Abstract][Full Text] [Related]
10. The mystery of PCSK9.
Attie AD
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1337-9. PubMed ID: 15297287
[No Abstract] [Full Text] [Related]
11. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
Tavori H; Melone M; Rashid S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
[TBL] [Abstract][Full Text] [Related]
12. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
Tietge UJ
Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
[No Abstract] [Full Text] [Related]
13. PCSK9: a key modulator of cardiovascular health.
Seidah NG; Awan Z; Chrétien M; Mbikay M
Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
[TBL] [Abstract][Full Text] [Related]
14. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy.
Raal F; Panz V; Immelman A; Pilcher G
J Am Heart Assoc; 2013 Apr; 2(2):e000028. PubMed ID: 23537802
[TBL] [Abstract][Full Text] [Related]
15. [Effective LDL cholesterol reduction for high risk patients].
Einecke D
MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
[No Abstract] [Full Text] [Related]
16. [PCSK9 inhibitor is convincing a large analysis].
Schlimpert V
MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
[No Abstract] [Full Text] [Related]
17. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
[TBL] [Abstract][Full Text] [Related]
18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
19. Therapy and clinical trials.
Sodhi N; Krasuski RA
Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
[No Abstract] [Full Text] [Related]
20. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
